published on 03/17/2021 at 8:22 a.m.
(Boursier.com) — Novacyt announces the expansion of its VersaLab service with the launch of Mobile Processing Laboratories (MPL) to provide rapid polymerase chain reaction (PCR) tests on site. The tests will be performed using mid-nose nasal swabs which have been shown to be effective and well tolerated compared to the more invasive nasopharyngeal swabs in the preliminary analysis of the Queen Mary University of London clinical trial in nursing homes, presented by the group on November 16, 2020. VersaLab was launched in December 2020 to support screening for infectious diseases in the private sector, initially focused on Covid-19. This has enabled Novacyt to identify a growing number of mobile testing opportunities in the UK and overseas in the private sector.
Novacyt’s mobile processing laboratories (MPLs) will be fully equipped with its PROmate test and its q16 PCR test instruments. PROmate is the only direct Covid-19 PCR test approved by the Technical Validation Group (TVG) of the UK Department of Health and Social Affairs (DHSC). The work organization of the PROmate, which includes a viral inactivation buffer phase, means that mobile processing laboratories (MPLs) do not need a Category 2 laboratory to handle the live virus. Therefore, the cost of testing is reduced, as are the risks associated with handling live virus in a mobile test unit. This organization of tasks enables Novacyt to deliver rapid results to patients in less than 80 minutes. Novacyt is one of the first companies to offer mobile test units that deliver same-day, on-site results using the benchmark sensitivity and specificity of PCR technology.
With a pipeline of active opportunities, Novacyt believes that the development of VersaLab mobile processing laboratories (MPLs) could offer new opportunities for long-term revenue growth, as the private sector begins to take charge of the business. screening for Covid-19 to keep businesses operational and efficient. Novacyt is testing Mobile Processing Laboratories (MPLs) with several private testing partners (approved government test-to-release program customers) at different locations in the UK to facilitate international travel.
Each Mobile Processing Laboratory (MPL) is capable of processing up to 900 Covid-19 samples per day, depending on the client’s needs. This performance is suitable for many use cases such as testing in the workplace, in schools, and at sporting and musical events.
Novacyt is also validating the use of its SNPsig portfolio with PROmate to provide a mobile solution capable of detecting the initial strain of SARS-CoV-2 and identifying variants of concern to help healthcare providers. quickly identify the appearance of secondary infections in localized areas.
©2021, Boursier.com
–
